
Leukemia
Latest News
Video Series

Latest Videos
Shorts










Podcasts
More News

The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.

Data from the phase BRUIN CLL-313 and BRUIN CLL-314 trials support the approval of pirtobrutinib for patients with CLL or SLL in China.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.

Poster presentations at SOHO 2026 may inform practice across acute lymphoblastic leukemia, acute myeloid leukemia, and chronic lymphocytic leukemia.

Data from the phase 2 PARADIGM trial may support the use of less toxic, more gentle therapies for patients with acute myeloid leukemia.

In a real-world setting, venetoclax plus a hypomethylating agent produced a median overall survival of 13.0 months in newly diagnosed acute myeloid leukemia.

The FDA cited outstanding manufacturing observations while raising no concerns about clinical data, bioequivalence, or stability in its CRL.

Updated results from the phase 2 ELIANA trial support tisa-cel as definitive therapy for pediatric and young adult patients with relapsed/refractory B-ALL.

Pirtobrutinib plus venetoclax/rituximab reduced the risk of progression or death by 45% among those with CLL in the phase 3 BRUIN CLL-322 trial.

Courtney D. DiNardo, MD, MSCE, and Michael R. Savona, MD, discussed how fast oral DEC-C plus venetoclax may replace IV HMA regimens in AML.

Phase 3 data may support orelabrutinib as a safe and effective option for patients with treatment-naïve CLL or SLL.

Amer Zeidan, MBBS, MD, discusses whether the expanding lower-intensity arsenal has narrowed the definition of a patient with AML who is unfit.

Amer Zeidan, MBBS, MD, discusses how mutation status and physical fitness factor into frontline AML regimen selection.

Amer Zeidan, MBBS, MD, discusses why real-world venetoclax dose modifications do not appear to compromise response durability in AML.

Amer Zeidan, MBBS, MD, discusses how the newly approved all-oral decitabine/cedazuridine plus venetoclax regimen fits into frontline AML care.




























































































